Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Can-Fite BioPharma ( (CANF) ).
On December 26, 2025, Can-Fite BioPharma announced that Brazil’s patent office granted a patent protecting the use of its A3 adenosine receptor agonist technology for the treatment of sexual dysfunction, extending its intellectual property coverage to one of Latin America’s largest pharmaceutical markets. The patent reinforces the therapeutic potential of Can-Fite’s A3AR platform in sexual health, complements its broader oncology and inflammatory disease programs, and may enhance the company’s strategic positioning and future commercial or partnering prospects in the region by leveraging preclinical and clinical data that link A3 receptor activation to vascular and metabolic pathways underlying erectile and sexual function.
The most recent analyst rating on (CANF) stock is a Hold with a $0.20 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
Spark’s Take on CANF Stock
According to Spark, TipRanks’ AI Analyst, CANF is a Neutral.
The score is held down primarily by weak financial performance (ongoing losses, declining revenue, and negative free cash flow) and a strongly bearish technical setup (price below all key moving averages with negative MACD). Valuation impact is neutral because P/E and dividend data are not available.
To see Spark’s full report on CANF stock, click here.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. is an advanced clinical-stage biotechnology company developing proprietary A3 adenosine receptor agonist small-molecule drugs for multi-billion-dollar markets in cancer, liver, inflammatory and sexual health diseases. Its lead candidates include Piclidenoson, which has reported Phase III topline results in psoriasis and entered a pivotal Phase III trial, and Namodenoson, now in Phase III for hepatocellular carcinoma, Phase IIb for MASH and Phase IIa for pancreatic cancer with orphan and fast-track status, while a third candidate, CF602, has shown efficacy in treating erectile dysfunction, supported by safety data from more than 1,600 patients.
Average Trading Volume: 9,495,383
Technical Sentiment Signal: Sell
Current Market Cap: $24.6M
See more insights into CANF stock on TipRanks’ Stock Analysis page.